Abstract: The present invention aims to provide a novel compound having a TRPA1 antagonist activity, and a medicament containing the compound. Moreover, the present invention aims to provide a TRPA1 antagonist and a medicament useful for the prophylaxis or treatment of diseases involving TRPA1. A medicament containing a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof, and the like.

Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof. The compound has a superior TRPA1 antagonist activity, and can provide a medicament useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

Abstract: The present invention provides a blood glucose elevation inhibitor having a serine protease inhibitory action, which is a novel therapeutic or prophylactic agent for obesity. A compound represented by the following formula (I) wherein each symbol is as described in the specification, or a pharmaceutically acceptable salt thereof.

Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: A process for producing a sheet-shaped prepreg includes: a fiber bundle introduction step in which tape-shaped reinforcing fiber bundles are disposed in a multilayer arrangement in the thickness direction and introduced into a die to which a molten thermoplastic resin has been supplied; a fiber bundle thickness reduction step in which each of the tape-shaped reinforcing fiber bundles is widened by means of spreading to reduce the thickness; a resin impregnation step in which the tape-shaped reinforcing fiber bundles are impregnated with the molten resin in the die; and a lamination step in which the plurality of resin-impregnated tape-shaped reinforcing fiber bundles are laminated in the die.

Abstract: A gate valve is configured to have a first fluid flow path. In a state where a gate valve pin is at a first pin position, a front end section on an injection hole side of the gate valve pin closes an injection hole. In a state where the gate valve pin is at a second pin position that is more distant from the injection hole than the first pin position, a front end section opens the injection hole to make communication between the first fluid flow path and the injection hole and thereby form a resin supply line. In a state where a sleeve is at a first sleeve position and the gate valve pin is at the first pin position, a second fluid flow path is formed in the gate valve to connect an injection hole-side end of the first fluid flow path to outside of the gate valve and is made to communicate with the first fluid flow path and thereby form a cleaning line.

Abstract: A method produces a reinforcing fiber sheet in which a plurality of bundles of reinforcing fibers lined up into one direction to form a plane are adhered to one another through a binder in an amount far smaller than that of the bundles. This method includes step (a) of placing a plurality of reinforcing fibers each having any length at any position on a flat plate, and fixing the reinforcing fibers onto the flat plate, step (b) of placing a binder onto the reinforcing fibers to be adhered onto the fibers, and step (c) of separating the reinforcing fibers from the flat plate.

Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: An object is to provide a novel compound having a higher MGAT2 inhibitory activity than conventional compounds. A compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof is provided.

Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: Compound represented by formula (I): wherein each symbol is as defined herein, exhibit TRPA1 antagonist activity, and are useful for the prophylaxis or treatment of diseases involving TRPA1 antagonist and TRPA1.

Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: Compounds represented by the following formula (I), are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: Compounds represented by the following formula (I); wherein each symbol is as defined in the specification, are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: A gate valve is configured to have a first fluid flow path. In a state where a gate valve pin is at a first pin position, a front end section on an injection hole side of the gate valve pin closes an injection hole. In a state where the gate valve pin is at a second pin position that is more distant from the injection hole than the first pin position, a front end section opens the injection hole to make communication between the first fluid flow path and the injection hole and thereby form a resin supply line. In a state where a sleeve is at a first sleeve position and the gate valve pin is at the first pin position, a second fluid flow path is formed in the gate valve to connect an injection hole-side end of the first fluid flow path to outside of the gate valve and is made to communicate with the first fluid flow path and thereby form a cleaning line.

Abstract: A carbon fiber preform has a plurality of carbon fiber sheets that are stacked and are bonded to each other by means of an adhesive resin having thermal plasticity. This carbon fiber preform comprises a partial-conducting layer arranged at least either between at least one pair of adjacent layers of the plurality of carbon fiber sheets or on a surface area of the plurality of carbon fiber sheets and configured to have a resistance area which has higher electric resistance than electric resistance of the carbon fiber sheet in a stacking direction and a conductive area which is capable of having electrical continuity in the stacking direction, wherein the resistance area and the conductive area are arranged in a surface direction orthogonal to the stacking direction. The plurality of carbon fibers sheets are bonded to each other by means of the adhesive resin in the surface direction in the conductive area and in an area corresponding to periphery of the conductive area.

Abstract: A process for producing a beam member formed by a reinforcing fiber base material which has a web portion and at least a pair of flange portions extending to both sides via at least a branching point from the web portion, at a cross-sectional surface orthogonal to a longitudinal direction of the beam member, and by a shaped filler which fills a gap having a wedge shape formed at the branching point, is provided. The shaped filler is produced by: (A) a filler supply process for supplying a filler member configured by reinforcing fibers; (B) a preshaping process for providing a preshaped filler having at least a wedge projection portion, by pressurizing the filler member by a preshaping mold; and (C) a filler deforming process for providing a shaped filler by deforming the preshaped filler.

Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.

Abstract: The present invention aims to provide a novel compound having a TRPA1 antagonist activity, and a medicament containing the compound. Moreover, the present invention aims to provide a TRPA1 antagonist and a medicament useful for the prophylaxis or treatment of diseases involving TRPA1. A medicament containing a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof, and the like.

Abstract: Compounds represented by formula (I): wherein each symbol is as defined in the description, and pharmaceutically acceptable salts thereof are useful as hyperglycemic inhibitors having a serine protease inhibitory action and as prophylactic or therapeutic drugs for diabetes.